Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Laurent Detalle
1
,
Thomas Stöhr
1
,
Concepción Palomo
2
,
Pedro A. Piedra
3, 4
,
Brian E. Gilbert
3
,
Vicente Más
2
,
Andrena Millar
5
,
Ultan F Power
5
,
Catelijne Stortelers
1
,
Koen Allosery
1
,
Jose A. Melero
2
,
Erik Depla
1
1
Ablynx nv, Zwijnaarde, Belgium
|
2
3
Publication type: Journal Article
Publication date: 2016-01-09
scimago Q1
wos Q1
SJR: 1.431
CiteScore: 8.4
Impact factor: 4.5
ISSN: 00664804, 10986596
PubMed ID:
26438495
Pharmacology
Infectious Diseases
Pharmacology (medical)
Abstract
ABSTRACT
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
|
|
|
Frontiers in Immunology
12 publications, 4.67%
|
|
|
Scientific Reports
8 publications, 3.11%
|
|
|
Antimicrobial Agents and Chemotherapy
7 publications, 2.72%
|
|
|
Nature Communications
7 publications, 2.72%
|
|
|
Viruses
5 publications, 1.95%
|
|
|
International Journal of Molecular Sciences
5 publications, 1.95%
|
|
|
Journal of Virology
5 publications, 1.95%
|
|
|
Microorganisms
4 publications, 1.56%
|
|
|
Pharmacology and Therapeutics
4 publications, 1.56%
|
|
|
International Journal of Biological Macromolecules
4 publications, 1.56%
|
|
|
mAbs
4 publications, 1.56%
|
|
|
Antibodies
3 publications, 1.17%
|
|
|
Frontiers in Microbiology
3 publications, 1.17%
|
|
|
Frontiers in Pharmacology
3 publications, 1.17%
|
|
|
Journal of Nanobiotechnology
3 publications, 1.17%
|
|
|
Expert Opinion on Pharmacotherapy
3 publications, 1.17%
|
|
|
Drug Discovery Today
3 publications, 1.17%
|
|
|
International Journal of Pharmaceutics
3 publications, 1.17%
|
|
|
Antiviral Research
3 publications, 1.17%
|
|
|
Science
3 publications, 1.17%
|
|
|
bioRxiv
3 publications, 1.17%
|
|
|
Biomolecules
3 publications, 1.17%
|
|
|
Expert Opinion on Drug Delivery
2 publications, 0.78%
|
|
|
Journal of Biological Chemistry
2 publications, 0.78%
|
|
|
Cell Reports
2 publications, 0.78%
|
|
|
iScience
2 publications, 0.78%
|
|
|
Advanced Drug Delivery Reviews
2 publications, 0.78%
|
|
|
Journal of Controlled Release
2 publications, 0.78%
|
|
|
Vaccine
2 publications, 0.78%
|
|
|
2
4
6
8
10
12
|
Publishers
|
10
20
30
40
50
60
70
|
|
|
Elsevier
64 publications, 24.9%
|
|
|
Springer Nature
51 publications, 19.84%
|
|
|
MDPI
25 publications, 9.73%
|
|
|
Taylor & Francis
21 publications, 8.17%
|
|
|
Cold Spring Harbor Laboratory
21 publications, 8.17%
|
|
|
Frontiers Media S.A.
20 publications, 7.78%
|
|
|
American Society for Microbiology
14 publications, 5.45%
|
|
|
Wiley
9 publications, 3.5%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 1.56%
|
|
|
SAGE
2 publications, 0.78%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.78%
|
|
|
Oxford University Press
2 publications, 0.78%
|
|
|
American Physiological Society
2 publications, 0.78%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.78%
|
|
|
The American Association of Immunologists
1 publication, 0.39%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.39%
|
|
|
Microbiology Society
1 publication, 0.39%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.39%
|
|
|
American Chemical Society (ACS)
1 publication, 0.39%
|
|
|
Royal Society of Chemistry (RSC)
1 publication, 0.39%
|
|
|
Pleiades Publishing
1 publication, 0.39%
|
|
|
IntechOpen
1 publication, 0.39%
|
|
|
Publishing House OKI
1 publication, 0.39%
|
|
|
eLife Sciences Publications
1 publication, 0.39%
|
|
|
Annual Reviews
1 publication, 0.39%
|
|
|
SPb RAACI
1 publication, 0.39%
|
|
|
Federal Medical Biological Agency
1 publication, 0.39%
|
|
|
Spandidos Publications
1 publication, 0.39%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.39%
|
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
257
Total citations:
257
Citations from 2024:
58
(22%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Detalle L. et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.
GOST all authors (up to 50)
Copy
Detalle L., Stöhr T., Palomo C., Piedra P. A., Gilbert B. E., Más V., Millar A., Power U. F., Stortelers C., Allosery K., Melero J. A., Depla E. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection // Antimicrobial Agents and Chemotherapy. 2016. Vol. 60. No. 1. pp. 6-13.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1128/aac.01802-15
UR - https://doi.org/10.1128/aac.01802-15
TI - Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
T2 - Antimicrobial Agents and Chemotherapy
AU - Detalle, Laurent
AU - Stöhr, Thomas
AU - Palomo, Concepción
AU - Piedra, Pedro A.
AU - Gilbert, Brian E.
AU - Más, Vicente
AU - Millar, Andrena
AU - Power, Ultan F
AU - Stortelers, Catelijne
AU - Allosery, Koen
AU - Melero, Jose A.
AU - Depla, Erik
PY - 2016
DA - 2016/01/09
PB - American Society for Microbiology
SP - 6-13
IS - 1
VL - 60
PMID - 26438495
SN - 0066-4804
SN - 1098-6596
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2016_Detalle,
author = {Laurent Detalle and Thomas Stöhr and Concepción Palomo and Pedro A. Piedra and Brian E. Gilbert and Vicente Más and Andrena Millar and Ultan F Power and Catelijne Stortelers and Koen Allosery and Jose A. Melero and Erik Depla},
title = {Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2016},
volume = {60},
publisher = {American Society for Microbiology},
month = {jan},
url = {https://doi.org/10.1128/aac.01802-15},
number = {1},
pages = {6--13},
doi = {10.1128/aac.01802-15}
}
Cite this
MLA
Copy
Detalle, Laurent, et al. “Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 1, Jan. 2016, pp. 6-13. https://doi.org/10.1128/aac.01802-15.